BioSpace News Archive

Eli Lilly and Company and its wholly-owned subsidiary Avid Radiopharmaceuticals, announced the successful Phase III trial of a Positron Emission Tomography (PET) imaging agent, flortaucipr F 18, in identifying tau in the brains of late-stage Alzheimer’s patients.

Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

Mylan plunked down $463 million for Novartis’ cystic fibrosis products, which includes the TOBI Podhaler and TOBI solution.

Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) from the Ministry of Food and Drug Safety (MFDS) in South Korea.

Regeneus Ltd is pleased to provide an overview of its results for the financial year ended 30 June 2018.

SOTIO announces today the completion of the acquisition of Cytune Pharma by PPF. SOTIO will continue to develop the lead program SO-C101 (RLI-15) within its pipeline and intends to initiate first-in-human clinical trials in early 2019.

VTT Technical Research Centre of Finland has developed an efficient synthetic biology toolbox for industry and research organisations.

VALBIOTIS announces the appointment of Pascal SIRVENT to its Board of Directors.

Adocia today announced an update to the second arbitration against Eli Lilly & Company (“Lilly”) for misappropriation and misuse of Adocia’s confidential information and discoveries.

GENFIT today announces its participation in numerous investor healthcare conferences both in Europe and the United States.